Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Isatuximab With or Without Lenalidomide in High Risk Smoldering Multiple Myeloma (ISAMAR)
NCT02960555Phase 2Active, not recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Feb 2017
- Primary completion
- Apr 2027
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label trial of isatuximab in smoldering multiple myeloma (SMM) (2 cohorts), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Overall Response Rate at 6 months. Started Feb 2017; status: active, not recruiting.
02
Drugs
isatuximab
03
Conditions
smoldering multiple myeloma (SMM)
Beyond the preview
Go deeper on NCT02960555.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02960555.